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ABSTRACT
Fetal liver tyrosine kinase 3 (FLT3) mutations represent a powerful prognostic indicator in acute myeloid
leukemia (AML). Further, interaction between FLT3 and its ligand plays a role in normal hematopoiesis.
Accordingly, FLT3 mutations may affect mobilization of peripheral blood stem cells (PBSCs) and feasibility of
autologous stem cell transplantation (ASCT) in AML. We analyzed the effect of FLT3 mutations on mobili-
zation of CD34 cells and on PBASCT feasibility from 111 patients with AML, with a median age of 58 years
and normal karyotype. Overall, 23 patients (21%) had FLT3 mutations. The complete remission rate was 74%
and was not influenced by FLT3 mutations (73% for patients with FLT3 and 78% for those with FLT3; P 
.78). The successful mobilization rate was 79% and was comparable for patients with FLT3 and with FLT3
(P  .42). Median numbers of CD34 cells collected were 7.6  106/kg and 7.1  106/kg for patients with
FLT3 and those with FLT3, respectively (P .64). Among 73 patients evaluated for mobilization, feasibility
of ASCT was 71%, and there was no difference between patients with FLT3 (74%) and those with FLT3
(61%), P  .43. We conclude that the FLT3 mutations have no influence on mobilization of CD34 cells or on
feasibility of PBASCT in patients with AML and normal karyotype.
© 2006 American Society for Blood and Marrow Transplantation
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The clinical outcome of acute myeloid leukemia
AML) is extremely variable, ranging from survival of
few days to cure [1,2]. There is general agreement
hat the probability of long-term survival is directly
elated to cytogenetic abnormalities at presentation
3-6]. However, 50%-60% of patients with AML
isplay normal karyotypes at diagnosis and are classi-
ed into the group of intermediate prognosis [3-6].
ithin the past few years, the presence of an activat-
ng internal tandem duplication (ITD) in the jux-
amembrane domain of the tyrosine kinase receptor
ene fetal liver tyrosine kinase 3 (FLT3) has emerged ts a powerful prognostic indicator, ahead of cytoge-
etics, for predicting relapse [7-10]. In particular, pa-
ients with activating FLT3 mutations in the form of
n ITD or a point mutation in the activation loop
point mutations of Asp835 [FLT3/D835 mutations])
ave a signiﬁcantly higher risk of relapse in interme-
iate-risk AML, in which most patients present with
ormal karyotype [11]. In addition, FLT3 is prefer-
ntially expressed on the cell surface of hematopoietic
rogenitors [12-14], and the ligand of FLT3 (FL) is
xpressed as a membrane-bound or soluble form by
one marrow (BM) stroma cells [15]. It has been
isclosed that FL-FLT3 interaction plays an impor-
ant role in the maintenance, proliferation, and differ-
981
e
t
p
A
c
a
t
f
A
M
P
k
i
a
m
1
(
d
c
I
m
p
b
l
i
w
p
a
p
O
d
A
d
A
A
c
d
s
t
s
t
c
6
b
L
t
w
g
(
s
m
a
m
K
t
o
r
s
a
p
a
m
b
e
T
C
p
G
T
t
r
t
m
p
H
d
t
T
A
i
(
d
a
w
5
a
s
d
t
m
F
h
a
c
d
B
o
C
w
h
m
w
F. Ferrara et al.982ntiation of hematopoiesis [15]. Accordingly, muta-
ions of FLT3 could play a role in mobilization of
eripheral blood stem cells (PBSCs) in patients with
ML and, hence, affect feasibility of autologous stem
ell transplantation (PBASCT). In this study, we an-
lyzed the effect of FLT3 mutations on CD34-posi-
ive (CD34) cells mobilization and collection and on
easibility of ASCT in a series of 111 patients with
ML and normal karyotype.
ETHODS
atient Characteristics
One hundred eleven patients with normal
aryotype AML who were intensively treated at our
nstitution between April 2001 and June 2005 were
nalyzed. There were 68 male patients and 43 fe-
ale patients, with a median age of 58 years (range,
7-79 years). Cytogenetic Reverse Hot Giemsa
RHG)-banding analysis was performed with a stan-
ard method [16]. The deﬁnition of a cytogenetic
lone and descriptions of karyotypes followed the
nternational System for Human Cytogenetic No-
enclature. A minimum of 20 BM metaphases per
atient was required to be examined for a patient to
e classiﬁed as having normal karyotype. Morpho-
ogic types of AML according to the French-Amer-
can-British classiﬁcation [17] were as follows: M0
as found in 2 patients, M1 in 37 patients, M2 in 21
atients, M4 in 43 patients, and M5 in 8 patients. In
ll patients, diagnosis was conﬁrmed by immuno-
henotypic study, as previously described [18].
verall 96 patients (86%) were diagnosed as having
e novo AML, whereas 15 patients (14%), in whom
ML occurred after a previously diagnosed myelo-
ysplastic syndrome, had a diagnosis of secondary
ML.
nalysis of FLT3/ITDs and FLT3/D835 Mutations
Cell preparation and nucleic acid isolation. Mononu-
lear cells were isolated, by using the Ficoll-Hypaque
ensity gradient centrifugation method, from BM
amples collected for the diagnostic workup at presen-
ation of the disease. Cells were washed twice in saline
olution and resuspended in 2 aliquots for each pa-
ient. Total RNA was puriﬁed from a mononuclear
ell aliquot of 5 106 cells cryopreserved at80°C in
00 L of 4 M guanidinium isothiocyanate solution
uffer. The GenElute Total RNA kit (Sigma, Saint
ouis, Mo, USA) was used for extraction according to
he manufacturer’s directions. The quality of RNA
as assessed on ethidium bromide-stained 1% agarose
el containing 2.2 mol/L formaldehyde.
A reverse transcriptase polymerase chain reaction
PCR) assay was used to detect FLT3 ITD in patient
amples. pBrieﬂy, 1 g of total RNA was prewarmed for 10
inutes at 70°C and incubated for 10 minutes at 25°C
nd then for 45 minutes at 42°C in a 20-L reaction
ixture containing 10 mM Tris HCl (pH 8.3), 50 mM
Cl, 5 mM MgCl2, 1 mM of each deoxyribonucleo-
ide, 1 U of RNAsin (Amersham, Milan, Italy), 2.5 M
f random hexamers (Amersham), and 10 U of MoMLV
everse transcriptase (Amersham). The reaction was
topped by heating at 99°C for 3 minutes. Two 2-L
liquots of this reverse transcriptase solution was inde-
endently ampliﬁed by PCR in a ﬁnal 50-L volume of
mixture containing 10 mM Tris-HCl (pH 8.3), 50
M KCl, 2.5 mM MgCl2, 0.2 mM of each deoxyri-
onucleotide, 1 U of Taq polymerase, and 0.4 M of
ach of the following primers: 5=-TGTCGAGCAG-
ACTCTAAACA-3= (sense primer) and 5=-ATC-
TAGTACCTTCCCAAACTC-3= (antisense
rimer) for the ITD analysis and 5=-AGAAGAGGAG-
ACTTGAATGTGCTTA-3= (sense primer) and 3=-
CCATATGACCAGACATCACTCTTAAT-5= (an-
isense primer) for the D835 analysis. Ampliﬁcation
eaction consisted of 35 cycles with the following time/
emperature proﬁle: 95°C for 30 seconds, 65°C for 1
inute, and 72°C for 1 minute. The ampliﬁed PCR
roducts were subsequently analyzed by Denaturating
igh Plasma Liquid Chromatography (DHPLC) to
etermine the size of ITD fragment or the presence of
he D835 mutation.
reatment
Patients who were 60 years of age with de novo
ML were given induction treatment consisting of
darubicin 10 mg/m2 on days 1, 3 and 5; cytarabine
ARA-C) 100 mg/m2 as a continuous infusion (CI) on
ays 1-7; and etoposide 100 mg/m2 on days 1-4. After
chievement of complete remission (CR), patients
ere consolidated with the NOVIA regimen (ARA-C
00 mg/m2 every 12 hours on days 1-6 and mitox-
ntrone 10 mg/m2 on days 4-6). Granulocyte colony-
timulating factor (G-CSF; 10 g/kg) was added on
ay 15 from the start of NOVIA to induce mobiliza-
ion of CD34 cells. In 3 patients whose cells failed to
obilize after NOVIA (2 with FLT3 and 1 with
LT3), a further attempt was made with 1 cycle of
igh-dose ARA-C (3 g/m2 every 12 hours on days 1, 3,
nd 5). In patients 60 years old, induction treatment
onsisted of continuous sequential infusions of ﬂu-
arabine and ARA-C as previously reported [19].
rieﬂy, ﬂudarabine was administered at a loading dose
f 10 mg/m2 over 15 minutes on day 1 followed by a
I of 20 mg/m2 every 24 hours for 72 hours. ARA-C
as given at a loading dose of 390 mg/m2 over 3.5
ours after ﬂudarabine and then as a CI at 1440
g/m2 every 24 hours for a total of 96 hours. G-CSF
as added at day 15 at a dose of 5 g/kg. After CR,
atients were given an additional course shortened by
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FLT3 Mutations and Mobilization of Stem Cells in AML 983day (CI of ﬂudarabine for a total of 48 hours and CI
f ARA-C for a total of 72 hours). G-CSF at 10 g/kg
as added at day 15 after consolidation to shorten
eutropenia and mobilize hematopoietic precursors.
BSC Collection
White blood cell count and circulating CD34
ells in PB were monitored to determine the timing of
BSC harvest. Apheresis was performed when the
eripheral CD34 cell count was 20  106/L by
sing a Cobe Spectra (Cobe, Lakewood, CO) cell sep-
rator processing 15 L of blood by continuous ﬂow. Set
s a target by our protocol, no additional apheresis was
lanned if the number of CD34 cells in the collected
pheresis product exceeded 2  106/kg body weight of
he patient.
Overall survival (OS) was deﬁned as the time from
iagnosis to death or ﬁnal follow-up. Disease-free
urvival (DFS) was deﬁned as the time from CR
chievement to relapse or death from any cause. DFS
nd OS were calculated by the Kaplan-Meier method
20]. Differences between survival curves were evalu-
ted by log-rank test. Differences in the distribution
f individual parameters among patient subsets were
nalyzed with the chi-square or Mann-Whitney test.
ll statistical comparisons used 2-tailed P values. P 
05 deﬁned statistical signiﬁcance.
able 1. Characteristics of Patients According to FLT3 Status
FLT3s FLT3s P
umber of patients (total 111) 88 (79%) 23 (21%)
ale/female 59/29 9/14 .39
edian age (range) 60 (17-79) 57 (22-73) .41
AB distribution
M0 2 0 .23
M1 26 11
M2 15 6
M4 38 5
M5 7 1
e novo/secondary 75/13 21/2 .67
BC count at diagnosis (109/L) 7.65 25.4 .004
PB blasts 58 79 .002
BM blasts 75 93 .03
erum lactate dehydrogenase
(IU/L) 712 970 .01
BC indicates white blood cell.
able 2. Comparison of Stem Cell Mobilization Rate, Survival, and Fe
R rate
uccessful mobilization rate (73 patients evaluated)
edian CD34 cells collected (106/kg)
verall feasibility of ASCT (total patients  111)
easibility of ASCT for patients evaluated for mobilization of CD
arly relapse rate (before ASCT)ESULTS
etection of FLT3 Mutations and Influence
n CR Achievement
Overall, 23 of 111 patients (21%) had FLT3 mu-
ations. Speciﬁcally, FLT3/ITDs were detected in 14
f 111 patients (13%), and FLT3/D835 mutations
ere detected in 8 of 111 patients (7%). One patient
1%) had both abnormalities. The CR rate for the
ntire patient population was of 74% (82 of 111 pa-
ients) and was not inﬂuenced by the presence of
LT3 mutations (64 of 88 patients or 73% for FLT3
ersus 18 of 23 patients or 78% for FLT3; P  .78).
hite blood cell count (P  .004), lactate dehydro-
enase (P .01), and percentages of PB and BM blasts
P  .002 and P  .03) were signiﬁcantly higher in
atients with FLT3 than in those with FLT3.
ther clinical parameters did not differ according to
he presence or absence of FLT3 mutations (Table 1).
obilization of CD34 Cells and Feasibility
f ASCT
After CR achievement, 6 patients underwent ASCT
nd were excluded from the analysis; 3 patients (all
ith FLT3) who were no longer eligible for further
reatment because of toxicity due to induction therapy
ere also excluded. The remaining 73 patients (55 with
LT3 and 18 with FLT3, respectively) were pro-
rammed to receive consolidation therapy and PBSCT.
mong these, the overall successful mobilization rate
2 106 CD34 cells/kg) was 79% (58 of 73) and was
omparable for patients FLT3 and those with FLT3,
e, 42 of 55 patients with FLT3 (76%) and 16 of 18
atients with FLT3 (89%); P  .42). Median num-
ers of CD34 cells collected were 7.6  106/kg
range, 2.1-50.8) and 7.1  106/kg (range, 4.4-60.3)
or patients with FLT3 and those with FLT3, re-
pectively (P  .64). Overall, ASCT was actually per-
ormed in 52 of 111 patients (47%); speciﬁcally, 41 of 88
atients with FLT3 (47%) received the procedure as
pposed to 11 of 23 (48%) with FLT3 (P  .89).
mong 73 patients evaluated for mobilization, feasibility
f ASCT increased to 71%, and there was no difference
etween patients with FLT3 (41 of 55 or 74%) and
hose with FLT3 (11 of 18 or 61%; P  .43). These
esults are summarized in Table 2, and Figure 1 shows
of ASCT Between FLT3 and FLT3 AML Patients
FLT3s FLT3s P
64/88 (73%) 18/23 (78%) .78
42/55 (76%) 16/18 (89%) .42
7.6 (2.1-50.8) 7.1 (4.4-60.3) .64
41/88 (47%) 11/23 (48%) .89
lls (n  73) 41/55 (74%) 11/18 (61%) .43asibility
34 ce
5/14 (36%) 5/7 (71%) .27
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F. Ferrara et al.984he progressive loss of patients from CR achievement to
SCT for the 2 patient subgroups we considered. Rea-
ons for not performing autografting in the remaining 21
atients (29%) included early relapse before PBASCT
n 10), toxicity after consolidation (n  5), and failure
o mobilize PBSCT (n  6). Of note, early relapse rate
as higher for patients with FLT3 (5 of 7, or 71%)
han for those with FLT3 (5 of 14, or 36%; P  .27).
linical Relevance of FLT3 Mutations
We also analyzed the clinical signiﬁcance of FLT3
utations. The median survival for 73 patients who
chieved CR and were scheduled to receive ASCT was
9 months, and the median DFS was 14 months.
edian OS and DFS for 52 autografted patients were
2 and 15 months, respectively. All patients were con-
itioned with a CI of idarubicin and oral busulphan,
ith a schedule adapted by age as previously described
21,22], and there was no early transplant-related
ortality (within 100 days). As indicated in Figure 2,
mong patients who underwent autografting, OS and
FS were similar between those with and without
LT3 mutations (median OS, 22 versus 20 months;
 .75; median DFS, 15 versus 16 months; P  .78).
onversely, among the 21 patients who did not un-
ergo autografting, median DFS was signiﬁcantly
horter for patients with FLT3 (7 versus 14 months;
 .05) due to higher incidence of early relapse.
ISCUSSION
Mutations leading to the constitutive activation of
LT3 receptor have been identiﬁed as the most fre-
uent genetic disorder in AML and confer a poor
linical prognosis in patients with intermediate cy-
ogenetics, most of whom have normal karyotype
23-26]. However, ligand-mediated activation of the
igure 1. Flow chart showing the progressive decrease in patients
rom diagnosis to PBASCT. No difference was found between
atients with FLT3 and those with FLT3.LT3 receptor is important for normal proliferation 1f primitive hematopoietic cells and for their interac-
ion with stromal cells [27]; therefore, the presence of
LT3 mutations may affect stem cell mobilization
ate and efﬁciency in patients with AML. In this study,
e investigated the effect of FLT3 mutations on mo-
ilization of PBSCs and on the feasibility of PBASCT
n a series of 111 consecutive patients with AML and
ormal karyotype. Overall, FLT3 mutations were re-
ated to high white blood cell counts, high percentages
f PB and BM blasts, and high serum lactate dehydro-
enase levels, conﬁrming a tendency toward a more
ggressive disease. However, no effect was observed
ith respect to CR achievement between patients with
LT3 and those with FLT3. These results are not
igniﬁcantly different from those recently reported in
ll patients who entered into the UK MRC AML10
nd AML12 trials [28]. In our study, patients with
econdary AML were also included; however, there
as no difference between patients with FLT3 and
hose with FLT3- with respect to the percentage of
econdary AML. Accordingly, this should have not
ccounted for therapeutic results. Then we focused on
group of 73 patients in CR1 who were evaluated for
obilization of CD34 cells and for feasibility of
BASCT. A main ﬁnding of our study was that mo-
ilization rate or median number of stem cells col-
ected after mobilization therapy followed by G-CSF
as similar between FLT3 and FLT3 subgroups,
igure 2. A. OS by FLT3 positivity (dotted line) or negativity
continuous line; median, 22 versus 20 months; P .73). B. DFS by
LT3 positivity (dotted line) or negativity (continuous line; median,
5 versus 16 months; P  .78).
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FLT3 Mutations and Mobilization of Stem Cells in AML 985uggesting that the presence of mutations do not af-
ect the differentiation pathway of normal immature
ematopoietic progenitor cells and their interactions
ith marrow stromal cells. Of note, feasibility of
BASCT was also comparable between the 2 groups,
ven though a tendency toward higher early relapse
hile waiting for ASCT was observed for patients
ith FLT3 (71% versus 36%). Although such a
ifference does not reach the level of statistical signif-
cance, it is conceivable that this is mainly due to the
mall number of patients analyzed. Other large series
ave reported signiﬁcantly higher relapse rates for
atients with FLT3 compared with controls, mainly
n patients with AML and intermediate cytogenetics
23-26]. No difference was found in terms of DFS or
S for patients who actually received autografts, sug-
esting that myeloablative therapy followed by autol-
gous stem cell infusion may overcome the adverse
rognostic effect of FLT3 mutations. Clearly, such a
nding needs to be conﬁrmed in a larger series;
onetheless, a recent paper by Yoshimoto et al re-
orted comparable results [29]. In addition, a sig-
iﬁcant decrease in relapse rate for FLT3 AML
as reported in patients randomized to receive
SCT in the MRC series, even though this did not
ranslate to an OS advantage [28]. Further, despite the
imited number of patients, the clinical outcome was
igniﬁcantly worse for patients with FLT3 who
chieved CR but were judged to be ineligible for
urther consolidation therapy.
Worthy of note, no case of transplant-related
ortality occurred in the present series. The use in all
ases of an adequate number of PBSCs, resulting in a
elatively short duration of neutropenia and thrombo-
ytopenia after conditioning, may have substantially
ccounted for these favorable results.
In conclusion, the analysis of our data demonstrate
hat the presence of FLT3 mutations has no inﬂuence
n mobilization and collection of CD34 cells in
atients with AML and normal karyotype and in over-
ll feasibility of PBASCT.
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